Kern David M, Mellström Carl, Hunt Phillip R, Tunceli Ozgur, Wu Bingcao, Westergaard Mogens, Hammar Niklas
a HealthCore Inc. , Wilmington , DE , USA ;
b AstraZeneca Pharmaceuticals , Mölndal , Sweden ;
Curr Med Res Opin. 2016;32(4):703-11. doi: 10.1185/03007995.2015.1136607. Epub 2016 Feb 10.
To quantify clinical and cost long-term outcomes in cardiovascular stable post-myocardial-infarction patients.
Subjects with a history of myocardial infarction (MI) who were 50-64 years old and MI- and stroke-free for ≥12 months (index date) were identified in a large US claims database. Individuals were followed for up to 5 years (mean: 2.0 years) after their index date.
Rates of MI, stroke, all-cause death, and a composite of these were analyzed via Cox regression models, adjusted for covariates. Results are reported for the overall population and the subgroups of those with type 2 diabetes, additional prior MI, and non-end-stage renal disease. As a secondary endpoint healthcare costs were evaluated at baseline and during each year of follow-up. Results Over the follow-up period, which averaged 2 years, 7.6% of all 13,492 subjects (10.5% vs. 5.4% with and without the selected risk factors, respectively) experienced at least one of the outcome events. The cumulative incidence rates over the entire follow-up period for the primary composite outcome were 20.8% and 12.2% for those with and without the selected atherothrombotic risk factors, respectively. The cardiovascular-related per-person-per-year healthcare costs during follow-up were higher in those with ≥1 additional risk factor compared to those without: $15,247 versus $7521. Costs were elevated over baseline costs throughout follow-up.
Administrative claims data lack clinical detail. Generalizability of results is limited to the US commercially insured population of a similar age to that included in this study.
High risk MI survivors who have been event free for ≥1 year remained at substantial risk of CV events and had increased healthcare costs for up to 5 years post-MI. These long-term risks have not been previously demonstrated in a working-age US population and suggest an unmet need for continuing secondary prevention long-term post-MI.
量化心肌梗死后心血管稳定患者的临床和成本长期结局。
在美国一个大型索赔数据库中识别出年龄在50 - 64岁、心肌梗死(MI)病史且自索引日期起无MI和中风≥12个月的受试者。个体在索引日期后随访长达5年(平均:2.0年)。
通过Cox回归模型分析MI、中风、全因死亡以及这些指标的综合发生率,并对协变量进行调整。报告总体人群以及2型糖尿病患者、既往有额外MI患者和非终末期肾病患者亚组的结果。作为次要终点,在基线和随访的每年评估医疗保健成本。结果在平均2年的随访期内,13492名受试者中有7.6%(有和无选定风险因素的分别为10.5%和5.4%)经历了至少一项结局事件。主要综合结局在整个随访期的累积发生率,有选定动脉粥样硬化血栓形成风险因素的患者为20.8%,无该风险因素的患者为12.2%。随访期间,有≥1个额外风险因素的患者每人每年的心血管相关医疗保健成本高于无额外风险因素的患者:分别为15247美元和7521美元。整个随访期间成本均高于基线成本。
行政索赔数据缺乏临床细节。结果的可推广性仅限于与本研究纳入的年龄相似的美国商业保险人群。
心肌梗死后无事件发生≥1年的高危幸存者在心肌梗死后长达5年仍有发生心血管事件的实质性风险且医疗保健成本增加。这些长期风险此前未在美国工作年龄人群中得到证实,表明心肌梗死后长期持续二级预防存在未满足的需求。